ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Eisai reboots search for blockbuster Alzheimer's drug

Failure to strike gold with Aduhelm prompts renewed focus on successor

Eisai has been the only Japanese pharmaceutical company with a heavy focus on neurocognitive disorders. (Photo by Kosaku Mimura)

TOKYO -- Japanese pharmaceutical group Eisai has essentially given up on a prospective blockbuster Alzheimer's disease drug and will instead focus resources on developing a follow-up offering.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more